Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02280473 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 188
- Enrollment target
NCT02280473: Completed Phase 3 study, sponsored by Allergan.
NCT02280473 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 188 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02280473, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 188 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.
Primary Outcome
The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.
Interventions
- DRUG Refresh Optive® Gel Drops
- DRUG REFRESH LIQUIGEL®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2014-11-13 |
| Est. Completion | 2015-03-16 |
| Phase | Phase 3 |
What the finished NCT02280473 record still lists
NCT02280473 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Refresh Optive® Gel Drops is the first listed.
NCT02280473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02280473 about?
NCT02280473 is a clinical study titled "A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease". This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.
What is the current status of trial NCT02280473?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 188 participants. The study started on 2014-11-13. Estimated completion is 2015-03-16.
What interventions are being tested in trial NCT02280473?
The interventions under investigation include: Refresh Optive® Gel Drops (DRUG), REFRESH LIQUIGEL® (DRUG).
Who is sponsoring clinical trial NCT02280473?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02280473's enrollment target sits among peer trials
188 1408th of 2000 higher than 591 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI